Skip to content

Dr. Saporito Giorgia

Orthoptist, Ophthalmic Assistant
FondazioneBietti_Saporito Giorgia
Research line: Research Line of Glaucoma and anterior segment with ocular annexes
Research unit: RU Glaucoma
Simple Operating Unit: Simple Operating Unit Glaucoma and Hospital-Territory Integration 
Specialization: Orthoptist, Ophthalmic Assistant
Professional register: Registered with the Professional Order of Health Technicians in Medical Radiology and Technical Health Professions in Rehabilitation and Prevention of Rome and Province, Registration No. 226, dated September 2, 2019.

Practices at IRCCS Fondazione G.B. Bietti, in the facilities of Via Livenza, 3 and Via di Santo Stefano Rotondo, 6, at the Presidio Ospedaliero Britannico, Rome.

 

  • 2018: Degree in Orthoptics and Ophthalmic Assistance from the “Tor Vergata” University of Rome (Italy), graduating with a final mark of 110/110 cum laude (highest honors).
  • 2014: High School Diploma (Linguistics Experimental Lyceum Bertrand Russell, Via Tuscolana 208, Rome (Italy)).
  • 2020 – Present: Orthoptist and Ophthalmic Assistant at IRCCS Fondazione G.B. Bietti.
  • Technical support activity for scientific research of the Glaucoma Operative Unit (UO).

Sub-Investigator for the following clinical trials:

  • Modulation of neuronal connectivity along the visual pathways in glaucomatous patients through treatment with citicoline in oral solution: multimodal morpho-functional study.
  • Efficacy and safety assessment of T4030 eye drops versus Ganfort® UD in ocular hypertensive or glaucomatous patients. LT4030-301.
  • A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension TRITON 1698-301-007.
  • Basic human research study of novel glaucoma endpoints and identification of optimal patient populations for neuroprotection trials CBASICHR0031.
  • Evaluation of spatial summation in the central 10 degrees of the visual field: development of a neural model for structure-function analysis.
  • Phase III, multinational, multicenter, investigator-masked, randomized, active-controlled study to compare the efficacy and safety of DE-130A versus Xalatan® in patients with open-angle glaucoma or ocular hypertension over 3 months, followed by a 12-month open-label follow-up with DE-130A treatment. CATIOPROST – 0130A01SA.
  • 24-hour efficacy and tolerability of the preservative-free fixed combination of tafluprost–timolol in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with BAK. A 3-month prospective, open-label study. HERO.
  • Evaluation of agreement in the diagnosis of glaucomatous visual field progression.
Skip to content